In the EuroVASC split lecture “Maintaining is enough?”, the SAB Chair frames why preserving the radial artery during compression is becoming a system-level priority, and where IDAHealth’s Guided Compression category fits.
AMSTERDAM, The Netherlands — On 6 June 2026, Dr. Giovanni Amoroso, MD, PhD, Medical Director and Co-Founder of IDAHealth Inc. and Chair of its Scientific Advisory Board, delivered a split lecture titled “Maintaining is enough?” within Session 4, “Minimally Invasive, Maximally Effective,” at the EuroVASC meeting. His talk addressed the lifetime management of radial access, the wrist artery now used as the default route for most heart catheterizations worldwide. The session prompted a notable interactive discussion: asked whether radial artery patency should be routinely assessed before discharge, 72 percent of participants agreed that it should.
After every wrist-access heart procedure, the artery is compressed for hours. The goal of that compression is dual: stop the bleeding while keeping the artery open. Doctors call this Patent Hemostasis. Every cardiology society recommends it. No device measures whether it is actually achieved.
That gap is the starting point for IDAHealth. Patent Hemostasis is two requirements held simultaneously. Dedicated compression devices solved the bleeding-control half in 2007. The patency half, keeping the artery open, is still delivered by intermittent manual checks that an operator interpolates between. For years the femoral artery served as a fallback when a radial artery was lost. As transradial access has become the default, at roughly 70 percent of procedures globally and climbing past 18 million procedures within five years, that fallback is disappearing, and the cost of the unmeasured half is now visible.
| PRESENTATION HIGHLIGHTS · EuroVASC 2026 • Interactive poll: 72 percent of participants agreed that radial artery patency should be routinely assessed before discharge. • A broader shift in interventional cardiology, from access success to access preservation, as transradial becomes the default strategy. • Preventing radial artery occlusion reframed as preserving future access options for patients, not only as avoiding an acute complication. |
Dr. Giovanni Amoroso, Medical Director and Co-Founder of IDAHealth Inc., delivering the split lecture “Maintaining is enough?” at EuroVASC 2026. During the session, 72 percent of participants agreed that radial artery patency should be routinely assessed before discharge. Photo: IDAHealth.
Why it matters
Radial artery occlusion runs at a 13 percent mean across 41 studies and roughly 30,000 patients (Khalid et al., Journal of Clinical Medicine 2024), within the 5 to 15 percent range reported in the 2026 position paper of the German Society of Cardiology (Breitbart et al., Die Kardiologie 2026). Radial artery occlusion is usually silent at the moment it occurs, because the hand keeps a second blood supply through the ulnar artery, yet transradial access is not free of under-recognized, potentially disabling complications (Wiper et al., 2020). The cost of a lost radial artery is deferred, not absent. Patients will need an open radial artery for a subsequent procedure, and discover the loss only when that artery is needed again.
At today’s volume of about 14.5 million transradial procedures a year, a 13 percent mean means roughly 1.9 million radial arteries are silently lost annually. Half of these patients will need that artery back. Some within a year, when staged PCI requires re-entry through the same site and roughly 15 percent develop restenosis. The rest later, when the radial is the preferred second conduit for coronary bypass surgery (a Class I recommendation, Level of Evidence B-R, 2021 ACC/AHA), or the access path for arteriovenous fistulas in dialysis.
Where Patent Hemostasis has been confirmed continuously rather than checked intermittently, results follow. In the largest published prospective dataset, mean hemostasis time fell from 190 minutes to 66 minutes (Takamatsu et al., 2023). IDAHealth will replicate this in its own trials, but the clinical evidence already exists, and clinicians are asking for a tool that delivers it.
The IDAHealth approach: Guided Compression
IDAHealth is building the category it calls Guided Compression: real-time, objective, data-generating monitoring of radial artery flow during the compression that follows every transradial procedure. Its first product, IdaFlo TR, is a single-use wristband sensor that attaches alongside any existing compression band and shows a real-time green, yellow, or red flow signal. It turns any compression band into a guided, measured device, the way continuous glucose monitors replaced finger-stick testing. The sensor is powered by IDASense, IDAHealth’s proprietary conductive elastomer sensor platform. IdaFlo TR completes the work the TR Band started in 2007: same clinical concept, two devices, nineteen years apart.
| “As transradial access has become the default, our focus is shifting from access success to access preservation. One of the most striking moments at EuroVASC was a simple question: should radial artery patency be routinely assessed before discharge? Seventy-two percent of the room agreed that it should. Preventing radial artery occlusion is not only about avoiding a complication, it is about preserving future access options for our patients. The difficulty is that you cannot preserve what you cannot measure, and that is exactly what Guided Compression is built to make possible.” Dr. Giovanni Amoroso, MD, PhD Medical Director and Co-Founder, IDAHealth Inc.; Chair, Scientific Advisory Board; Interventional Cardiologist, OLVG Amsterdam |
About the opportunity
IdaFlo TR pairs a reusable reader with a single-use sensor, a recurring-consumable model that scales with every transradial procedure performed. Each procedure also produces something that does not exist today: a continuous, objective record of the compression itself. Aggregated across patients, shifts, and sites, this becomes a Data-as-a-Service layer that supports hospital quality benchmarking and builds the real-world evidence base for regulatory and clinical reporting. The dataset compounds with every patient and cannot be replicated by a later entrant. IDAHealth’s patent family is granted in the United States, the European Union, Japan, China, and India, with protection extending toward 2040. The company was selected to the BDMT Global Top 40 in 2026. A first European clinical pilot cohort is committed across leading centers, including OLVG Amsterdam, UMons in Belgium, and Keele University in the United Kingdom, alongside sites in Germany.
About IDAHealth Inc.
IDAHealth Inc. is a medical device company creating the category of Guided Compression: real-time, objective monitoring of radial artery flow during the post-procedural compression that follows transradial catheterization. Its purpose is to establish Patent Hemostasis from minute one. The company’s first product, IdaFlo TR, is a single-use wristband sensor powered by the IDASense conductive elastomer platform that works alongside any existing compression band. IDAHealth is a Delaware C-Corporation with operations in the Netherlands. Learn more at www.idahealth-inc.com.
Media contact
David Camp
Co-Founder and CEO, IDAHealth Inc.
info@idahealth.us | www.idahealth-inc.com
16192 Coastal Highway, Lewes, DE 19958, USA | +1 954 806 2962
# # #
References
1. Khalid A, et al. Incidence and Predictors of Early and Late Radial Artery Occlusion after Percutaneous Coronary Intervention and Coronary Angiography: A Systematic Review and Meta-Analysis. J Clin Med. 2024;13(19):5882. https://doi.org/10.3390/jcm13195882
2. Breitbart P, et al. Verschlüsse der Arteria radialis nach Herzkathetereingriffen, DGK-Stellungnahme (position paper, German Society of Cardiology). Die Kardiologie. 2026;20:54-61. https://doi.org/10.1007/s12181-025-00776-2
3. Wiper A, Amoroso G, Rao S, Nolan J. Complex regional pain syndrome: a rare but potentially disabling complication of transradial cardiac catheterization. Catheter Cardiovasc Interv. 2020;95(5):E140-E143. https://doi.org/10.1002/ccd.28357
4. Takamatsu S, et al. Impact of radial compression protocols on radial artery occlusion and hemostasis time in coronary angiography. Cardiovasc Interv Ther. 2023. https://doi.org/10.1007/s12928-022-00896-6
5. Lawton JS, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. Circulation. 2022;145:e18-e114. https://doi.org/10.1161/CIR.0000000000001038Note to editors: the hemostasis-time figure (Takamatsu et al., 2023) is cited as existing clinical evidence in the field and is not an IDAHealth trial result. RAO incidence cites Khalid et al. 2024 for the 13 percent mean and Breitbart